Prince of Wales Hospital, Australia
Published: 3 Dec 2008
Views: 17659
Prof. Michael Friedlander
Investigational drug shows promise in ovarian cancer.
- Categories:
- Ovary & gynaecology
- Drug development
Related Videos
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refract...
Dr Claudio Cerchione - IRCCS, Meldola, Italy
23 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 4 and 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Jun 2021
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more...
Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA
4 Nov 2020
OncoAlert and ecancer weekly roundup for September 20 - 26, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
28 Sep 2020
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advan...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
20 Sep 2020
Management of advanced cervical cancer
Dr Avinash Pandey - State Cancer Institute, Patna, India
6 Mar 2020
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
7 Oct 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
28 Sep 2019
